Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab for Relapsed/Refractory PEL, PBL, and MCD
NCT05907759Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2024
- Primary completion
- Aug 2034
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in primary effusion lymphoma (PEL), plasmablastic lymphoma (PBL), multicentric Castleman disease (MCD), sponsored by National Cancer Institute. Started Jul 2024; status: recruiting.
02
Drugs
daratumumab
03
Conditions
primary effusion lymphoma (PEL)plasmablastic lymphoma (PBL)multicentric Castleman disease (MCD)
Beyond the preview
Go deeper on NCT05907759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05907759.